Moderna, Inc.

We are mRNA. And mRNA is us.

Every day, we come together to create the blueprints needed to fight and eradicate diseases, and to help people live healthier lives. And the world has witnessed the powerful benefits of our platform technology.

With mRNA technology, we are completely reimagining how medicines are created and delivered. And in the process, we’re launching an entirely new industry, one fueled by deep care for our teams as well as for others.

Through the power of mRNA, we’re giving our people a platform to change medicine—and an opportunity to change the world.

Come with us as we pursue the uncharted reaches of possibility and make your mark on the future of medicine: modernatx.com/careers

200 Technology Square
Cambridge, MA

Tel: 617-714-6500

Visit website

Email Us

Stock Symbol: MRNA
Stock Exchange: USNASDAQ GS

Changing the future of medicine starts with our people. Across Moderna, our colleagues are working to make the impossible possible, and our goal is to support them every step of the way. With a global team and a unique culture, driven by the company’s values and mindsets, Moderna’s mission is to deliver the greatest possible impact to people through mRNA medicines.

Every Role Matters, Enabling Transformative Mission

At Moderna, our changemakers are actively building a better future, one innovation at a time. We recently asked Keke if she could create a six-word story about what being a changemaker meant to her.

Read Keke’s Story

Take your moment with benefits

We know that you will give us your all and we want to make sure that we’re doing the same for you and the people closest to you. We’re on this incredible journey of pushing past the possible together, which is why we provide paramount support for both you and your family.

Learn More

NEWS

Deals

Updated: BioSpace’s List of December 2018 Life Sciences IPOs

A summary of IPOs from companies in the biotech and pharma world since December 1, 2018.

December 21, 2018

1 min read

Editorial Staff

Deals

A Look at the Year’s Most and Least Successful Biotech IPOs

Although the size of the IPO is one aspect of determining the success of a company’s public launch, it’s not the only metric. How the stock does in the ensuing months is a very important consideration.

December 19, 2018

4 min read

Mark Terry

Pharm Country

Top 10 Stories of 2018: BioSpace Writers Alex and Mark Pick Their Favorites

In writing literally hundreds of stories this year, two BioSpace writers, Alex Keown and Mark Terry, found certain stories particularly intriguing or impactful. Some of those were such big topics that they were covered over a series of stories. Looking back at 2018, here are their Top 10.

December 14, 2018

10 min read

Alex Keown and Mark Terry

Deals

A Record Year: A Look at the Biotech IPOs for Q4 2018

The Nasdaq indicated that there was a record amount of biotech initial public offerings this year, including some individual record-breakers—Moderna, Allogene Therapeutics and Rubius Therapeutics. The total for the year is around $8.2 billion raised, breaking 2014’s record of $6.5 billion.

December 11, 2018

4 min read

Mark Terry

Deals

Moderna Therapeutics Sets Record for Biggest Biotech IPO

The long-awaited and massively hyped initial public offering of Moderna Therapeutics hit the market yesterday. The company sold approximately 26.3 million shares priced at $23 a share. This exceeded the revised goal of $600 million by about $4.3 million.

December 7, 2018

4 min read

Mark Terry

Deals

Moderna’s $600 Million IPO: A Sign of Value or Just a Trend?

Moderna Therapeutics raised some eyebrows last week when it refiled with the Securities and Exchange Commission (SEC), raising its goal for its initial public offering from $500 million to $600 million. The company, which has no products on the market, is fantastic at raising money, but some analysts wonder if the company is overvalued.

December 6, 2018

3 min read

Mark Terry

Deals

Can Moderna Live up to the Hype? mRNA Company Increases IPO Goal to $600 Million

The Cambridge, Mass.-based biotech company, which had proposed a $500 million initial public offering (IPO) earlier this month, came back Wednesday with a new goal of $600 million.

November 29, 2018

3 min read

Mark Terry

Business

Roivant Sciences Raises $200 Million, Bringing Its Valuation to $7 Billion

Vivek Ramaswamy’s Roivant Sciences, the umbrella company to 14 Vant companies, including Datavant, Enzyvant Sciences, Urovant Sciences and others, raised another $200 million in equity financing.

November 13, 2018

3 min read

Mark Terry

Deals

Well-Funded Unicorn Moderna Therapeutics Eyes $500 Million IPO

As a private company, Moderna has amassed a significant fortune of billions of dollars and a valuation of about $7 billion – all of this without any marketed product in the company’s field of messenger RNA (mRNA).

November 12, 2018

2 min read

Alex Keown

JOBS